Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

The Seattle Times

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Monday, October 6, 2008 at 12:00 AM

Comments (0)     E-mail article     Print view

Dendreon shares leap on mixed news for Provenge

Dendreon's interim results from a trial of its prostate-cancer drug Provenge show mixed results, but stock soars anyhow.

Seattle Times business reporter

Dendreon said Monday that Provenge demonstrably improved survival among prostate cancer patients, according to long-awaited interim results from a clinical trial.

The results sent Dendreon shares soaring, but were not strong enough for the company to ask federal regulators for speedier approval. Instead, the Seattle biotech firm will await the final analysis, scheduled for mid-2009.

The news is "not as good as it could have been, nor as bad as it could have been," said Paul Latta, an analyst with McAdams Wright Ragen.

Dendreon shares traded at $6.93, up 33 percent, after jumping as high as $9 in early morning trading, against the dismal backdrop painted by a global financial shakeout.

Provenge, Dendreon's lead therapy, which would be the first commercial immunetherapy to fight cancer, if it is approved.

But it has been a roller-coaster ride for many investors. In early 2007 the company stock rode as high as $19 on hopes that the U.S. Food and Drug Administration would approve the product in May of that year.

But the agency decided to withhold approval, asking for more data instead. That triggered a sharp fall in the stock price and an angry response from prostate cancer patients eager for a promising treatment.

Hopes soared again when the FDA said it would look at the interim data presented today as sufficient to support an application for approval. But the data "did not meet the pre-specified criteria" for Dendreon to modify the marketing approval it has pending at the FDA, said Chief Executive Mitch Gold in a conference call.

In order to meet its goals, Dendreon needs to demonstrate a 22 percent reduction in the risk of death among patients using Provenge, based on 304 patients, the company said.

The final analysis of the data was originally due in 2010, but the last March company redesigned the clinical trial in order to fast-forwards the results by a year.

Ángel González: 206-515-5644 or agonzalez@seattletimes.com

Copyright © 2008 The Seattle Times Company

More Business & Technology headlines...

E-mail article Print view      Share:    Digg     Newsvine

Comments
No comments have been posted to this article. Start the conversation.

advertising

UPDATE - 07:50 AM
Bernanke outlines plan for pulling in stimulus aid

Lots of Buzz over Google latest bid at social networking

UPDATE - 08:06 AM
Stocks fall on Bernanke points to end of stimulus

UPDATE - 07:53 AM
AP sources: FAA eyes hefty fines for American

NEW - 08:30 AM
More recalls likely amid caution after Toyota woes

Advertising

Video

Marketplace

Open Houses

Find this weekend's open house listings.
Or search by location:

nwautos

Fatal crashes are down in Washington, and a national used-car database goes onlinenew
Associated Press Study: Fatal crashes down in Washington Last year Washington's roads were the scene of the fewest fatal crashes since 1955. According...
Post a comment

 
Most read
Most commented
Most e-mailed
 
 

Most viewed imagesMore

Advertising